Mix and Match COVID-19 Vaccines for Coronavirus Safety and Immunity
(MOSAIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the effectiveness of mixing and matching different COVID-19 vaccines for various doses and intervals. It will assess the immune response and safety of vaccines such as Pfizer (BNT162b2), Moderna (mRNA-1273 SARS-CoV-2 vaccine), AstraZeneca (ChAdOx1-S [recombinant]), and Covifenz. Participants who have received some COVID-19 vaccines or are vaccine-naïve are eligible to join. The trial suits individuals in good health or with stable, mild conditions, who have not experienced severe reactions to past vaccines. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant vaccine development.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on immunosuppressant medication or continuous anticoagulants, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the vaccines tested in this trial have been safe in past studies. The Pfizer-BioNTech vaccine, BNT162b2, has been used in trials and real-world settings without major safety issues. Some individuals might experience mild reactions, such as a sore arm or fatigue.
The AstraZeneca vaccine, ChAdOx1-S, is considered safe and effective. It is approved in many countries, with most side effects, like headaches or tiredness, being mild.
The Covifenz vaccine, derived from plants, has demonstrated good safety results in trials. Most reported side effects have been mild and short-lived.
Lastly, the Moderna vaccine, mRNA-1273, has been widely used and has a strong safety record. Most side effects, such as a sore arm or mild fever, are mild and temporary.
Overall, these vaccines have been well-tolerated in previous studies, with most side effects being mild and short-term.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the mix-and-match COVID-19 vaccine approach because it offers potential flexibility and enhanced immunity compared to standard vaccination protocols. Unlike traditional methods that stick to a single vaccine type, this strategy combines different vaccines, like Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273, potentially boosting immune response by leveraging varied mechanisms. Additionally, by testing vaccines such as Covifenz, which uses plant-based technology, this trial explores alternatives that could complement existing mRNA vaccines and help address global supply challenges. This innovative approach could lead to more personalized vaccine strategies, enhancing protection against COVID-19 variants.
What evidence suggests that this trial's treatments could be effective for COVID-19?
This trial will explore the effects of different COVID-19 vaccine combinations. Research has shown that the Pfizer-BioNTech vaccine, BNT162b2, is highly effective, with a 95% success rate in preventing COVID-19. Studies have also found that Moderna's mRNA-1273 vaccine is about 94.1% effective in stopping COVID-19, including severe cases. The AstraZeneca vaccine, ChAdOx1-S, is about 60.59% effective after the first dose in reducing the severity of COVID-19. The Covifenz vaccine, which is plant-based, has an effectiveness of 69.5% to 71% against COVID-19. All these vaccines have been shown to lower the risk of severe illness, hospitalization, and death from COVID-19. Participants in this trial will receive different combinations of these vaccines to assess safety and immunity.12678
Who Is on the Research Team?
Joanne Langley
Principal Investigator
Dalhousie University/CIRN
Are You a Good Fit for This Trial?
This trial is for adults over 18 who've had at least two COVID-19 vaccine doses ≥6 months ago, or are unvaccinated. They must be in good health or with stable conditions and not planning pregnancy soon. Those previously vaccinated can join if they're scheduled for their first dose within 55 days before the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose 1 and 2 Administration
Participants receive the first and second doses of the COVID-19 vaccine, with intervals of either 28 days or 112 days between doses.
Dose 3 Administration
Participants receive the third dose of the COVID-19 vaccine, anticipated to be administered 6 months after the second dose.
Dose 4 Administration
Participants receive the fourth dose of the COVID-19 vaccine, anticipated to be administered 3 months after the third dose.
Follow-up
Participants are monitored for safety and effectiveness after the vaccination schedule, with assessments of immune response and adverse events.
What Are the Treatments Tested in This Trial?
Interventions
- BNT162b2
- ChAdOx1-S [recombinant]
- Covifenz
- mRNA-1273 SARS-CoV-2 vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Immunization Research Network
Lead Sponsor
Children's Hospital Research Institute of Manitoba
Collaborator
CHU de Quebec-Universite Laval
Collaborator
Ottawa Hospital Research Institute
Collaborator
Ontario Agency for Health Protection and Promotion
Collaborator
University of Toronto
Collaborator
Massachusetts General Hospital
Collaborator
Interior Health
Industry Sponsor
Canadian Center for Vaccinology
Collaborator
BC Children's Hospital Research Institute
Collaborator